CoChat

Efficacy and safety of creatine supplementation in childhood-onset systemic lupus erythematosus: a randomized, double-blind, placebo-controlled, crossover trial

Hayashi, A P, Solis, M Y, Sapienza, M T, Otaduy, M C G, de Sá Pinto, A L, Silva, C A, Sallum, A M E, Pereira, R M R, Gualano, B · 2014 · Lupus

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Introduction: Creatine supplementation has emerged as a promising non-pharmacological therapeutic strategy to counteract muscle dysfunction and low lean mass in a variety of conditions, including in pediatric and rheumatic diseases. The objective of this study was to examine the efficacy and safety of creatine supplementation in childhood systemic lupus erythematosus (C-SLE). Methods: C-SLE patients with mild disease activity ( n = 15) received placebo or creatine supplementation in a randomized fashion using a crossover, double-blind, repeated-measures design. The participants were assessed at baseline and after 12 weeks in each arm, interspersed by an eight-week washout period. The primary outcomes were muscle function, as assessed by a battery of tests including one-maximum repetition (1-RM) tests, the timed-up-and-go test, the timed-stands test, and the handgrip test. Secondary outcomes included body composition, biochemical markers of bone remodeling, aerobic conditioning, quality of life, and physical capacity. Possible differences in dietary intake were assessed by three 24-hour dietary recalls. Muscle phosphorylcreatine content was measured through phosphorus magnetic resonance spectroscopy (31 P-MRS). The safety of the intervention was assessed by laboratory parameters, and kidney function was measured by 51 Cr-EDTA clearance. Additionally, self-reported adverse events were recorded throughout the trial. Results: Intramuscular phosphorylcreatine content was not significantly different between creatine and placebo before or after the intervention (creatine-Pre: 20.5 ± 2.6, Post: 20.4 ± 4.1, placebo-Pre: 19.8 ± 2.0; Post: 20.2 ± 3.2 mmol/kg wet muscle; p = 0.70 for interaction between conditions). In addition, probably as a consequence of the lack of change in intramuscular phosphorylcreatine content, there were no significant changes between placebo and creatine for any muscle function and aerobic conditioning parameters, lean mass, fat mass, bone mass, and quality of life scores ( p > 0.05). The 51 Cr-EDTA clearance was not altered by creatine supplementation and no side effects were noticed. Conclusion: A 12-week creatine supplementation protocol at 0.1 g/kg/d is well tolerated and free of adverse effects but did not affect intramuscular phosphorylcreatine, muscle function, free-fat mass or quality of life in non-active C-SLE patients. Trial registration: Clinicaltrials.gov number: NCT01217320.

Overview

Integrity signals

Registry

Crossref · 10.1177/0961203314546017

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 51 references

Research works printed but not linked: 5

  1. Alsufyani KA, 2005, J Rheumatol, 32, 729
  2. Kley RA, 2013, Cochrane Database Syst Rev, 6, CD004760
  3. Gladman DD, 2002, J Rheumatol, 29, 288
  4. Newcomer KL, 1993, J Rheumatol, 20, 21
  5. Machado CS, 2001, Clin Exp Rheumatol, 19, S25

Cited by

See all 36

Metadata

Authors
Hayashi, A. P., Solis, M. Y., Sapienza, M. T., Otaduy, M. C. G., de Sá Pinto, A. L., Silva, C. A., Sallum, A. M. E., Pereira, R. M. R., & Gualano, B.
Affiliations
  • School of Medicine
  • Universidade de São Paulo (BR)
Corresponding author
Gualano, B
Venue
Lupus
Published
2014-08-18
Volume
23
Issue
14
Pages
1500-1511
ISSN
  • 0961-2033 (ISSN-L)
  • 1477-0962
OpenAlex
W2074188667
Cited by
35
References
51
Citations by year
2026: 7 · 2025: 2 · 2024: 4 · 2023: 1 · 2022: 1 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 1
FWCI
1.16
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Lupus (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
Keywords
creatine supplementation, pediatric lupus, muscle function, lean body mass, body composition, bone remodeling, aerobic conditioning, quality of life, renal function, safety, pediatric rheumatic diseases, dietary intake, phosphorus magnetic resonance spectroscopy, Timed Up and Go test, grip strength, 51Cr-EDTA clearance
MeSH terms
Adolescent, Body Composition, Child, Creatine, Double-Blind Method, Exercise Test, Female, Humans, Lupus Erythematosus, Systemic, Magnetic Resonance Imaging, Male, Phosphocreatine, Quality of Life, Anaerobic Threshold, Bone Remodeling, Exercise Tolerance, Muscle, Skeletal, Cross-Over Studies, Hand Strength, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of creatine supplementation in childhood-onset systemic lupus erythematosus: a randomized, double-blind, placebo-controlled, crossover trial. https://app.cochat.ai/papers/10.1177/0961203314546017
The paper
Hayashi, A. P., Solis, M. Y., Sapienza, M. T., Otaduy, M. C. G., de Sá Pinto, A. L., Silva, C. A., Sallum, A. M. E., Pereira, R. M. R., & Gualano, B. (2014). Efficacy and safety of creatine supplementation in childhood-onset systemic lupus erythematosus: a randomized, double-blind, placebo-controlled, crossover trial. Lupus. https://doi.org/10.1177/0961203314546017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.